0001209191-18-019413.txt : 20180313
0001209191-18-019413.hdr.sgml : 20180313
20180313184143
ACCESSION NUMBER: 0001209191-18-019413
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180312
FILED AS OF DATE: 20180313
DATE AS OF CHANGE: 20180313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Barth Jay
CENTRAL INDEX KEY: 0001601896
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 18687915
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 662-2000
MAIL ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-12
0
0001178879
AMICUS THERAPEUTICS INC
FOLD
0001601896
Barth Jay
C/O AMICUS THERAPEUTICS, INC.
1 CEDAR BROOK DRIVE
CRANBURY
NJ
08512
0
1
0
0
Chief Medical Officer
Common Stock
2018-03-12
4
M
0
5000
2.29
A
90409
D
Common Stock
2018-03-12
4
S
0
5000
15.0505
D
85409
D
Common Stock
125
I
By Daughter
Stock Options (right to buy)
2.29
2018-03-12
4
M
0
5000
0.00
D
2024-03-03
Common Stock
5000
105000
D
The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.94 to $15.19. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the options were fully vested and exercisable as of March 12, 2018.
/s/ Jay Barth
2018-03-13